<DOC>
	<DOCNO>NCT00345176</DOCNO>
	<brief_summary>Oral supplementation Age-Related Eye Disease Study ( AREDS ) formulation ( antioxidant vitamin C E , beta carotene , zinc ) show reduce risk progression advance age-related macular degeneration ( AMD ) . Observational data suggest increase dietary intake lutein + zeaxanthin ( carotenoid ) , omega-3 long-chain polyunsaturated fatty acid ( docosahexaenoic acid [ DHA ] + eicosapentaenoic acid [ EPA ] ) , might reduce risk . AREDS2 design test whether add lutein + zeaxanthin , DHA + EPA , lutein + zeaxanthin DHA + EPA AREDS formulation might reduce risk progression advance AMD . A secondary goal test effect eliminate beta carotene reduce zinc dose AREDS formulation .</brief_summary>
	<brief_title>Age-Related Eye Disease Study 2 ( AREDS2 )</brief_title>
	<detailed_description>AREDS2 randomize , double-masked , placebo-controlled , 2x2 factorial trial evaluate risk benefit add lutein ( 10 mg ) + zeaxanthin ( 2 mg ) , DHA ( 350 mg ) + EPA ( 650 mg ) , AREDS formulation , consist vitamin C ( 500 mg ) , vitamin E ( 400 international unit ) , beta carotene ( 15 mg ) , zinc ( 80 mg zinc oxide ) , copper ( 2 mg cupric oxide ) treatment progression advance AMD . The study enrol 4,203 participant age 50 85 year , sufficiently clear ocular medium allow accurate assessment AMD fundus photograph . Subjects enrol basis AREDS Simplified Severity Scale define risk category development advance age-related macular degeneration . All participant offer additional treatment original AREDS formulation ( consider standard care ) 3 variation formula . These : ( 1 ) beta-carotene ; ( 2 ) low amount zinc ( 25 mg ) ; ( 3 ) beta-carotene lower amount zinc ( 25 mg ) . Eligible participant follow minimum five year . Multiple ancillary study conduct use parent study ( AREDS2 ) data explore : 1 . Effects oral supplementation omega-3 fatty acid , lutein/zeaxanthin , zinc , beta-carotene cognitive function 1 . Outcome measure battery test administer telephone baseline , year 2 4 study . 2 . Primary outcome change composite score result cognitive function test baseline time . 2 . Effects oral supplementation omega-3 fatty acid , lutein/zeaxanthin cardiovascular disease . Primary measure cardiovascular morbidity mortality 3 . Effects oral supplementation omega-3 fatty acid , lutein/zeaxanthin peripheral retina . Primary outcome development peripheral drusen , geographic atrophy , reticular pigmentary change , pseudoreticular drusen . 4 . Association genotype polymorphism age-related macular degeneration cataract . Whole genome sequencing complete . Evaluation association genetic association disease conduct use AREDS control . 5 . Association genotype polymorphism progression age-related macular degeneration . Whole genome sequencing conduct . Progression early late severe stage AMD examine genotype data evaluate risk progression associate genotype polymorphism . 6 . Association genotype polymorphism dietary intake . Whole genome sequencing conduct . Progression early late severe stage AMD examine regard potential interaction dietary intake genotype data evaluate risk progression . 7 . Association genotype polymorphism AREDS2 supplement a. Interaction genetic polymorphism AREDS2 supplement progression late AMD evaluate use data whole genome sequencing project .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Men woman age 50 85 year Macular status range large drusen eye large drusen one eye advance AMD ( neovascular AMD geographic atrophy ) fellow eye Ocular medium clear enough allow good fundus photography</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>age-related macular degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>lutein</keyword>
	<keyword>zeaxanthin</keyword>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>eicosapentaenoic acid</keyword>
</DOC>